Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cassava Sciences Inc Market Cap
From what 0 stock analysts predict, the share price for Cassava Sciences Inc (SAVA) might increase by 282.47% in the next year. This is based on a 12-month average estimation for SAVA. Price targets go from $75 to $131. The majority of stock analysts believe SAVA is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
SAVA is a stock in Health Care which has been forecasted to be worth $103 as an average. On the higher end, the forecast price is $131 USD by Vernon Bernardino from HC Wainwright & Co. and on the lower end SAVA is forecasted to be $75 by from .
These are the latest 20 analyst ratings of SAVA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Vernon Bernardino HC Wainwright & Co. | Neutral | Reiterates | Aug 13, 2024 | |
| Elemer Piros Rodman & Renshaw | Buy | $107 | Reiterates | Aug 8, 2024 |
| Vernon Bernardino HC Wainwright & Co. | Neutral | Reiterates | Jul 19, 2024 | |
| Soumit Roy Jones Trading | Hold | Downgrade | Jul 1, 2024 | |
| Vernon Bernardino HC Wainwright & Co. | Neutral | Downgrade | Jul 1, 2024 | |
| Vernon Bernardino HC Wainwright & Co. | Buy | $131 | Maintains | May 17, 2024 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $124 | Reiterates | Mar 5, 2024 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $124 | Reiterates | Aug 8, 2023 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $124 | Reiterates | Jul 6, 2023 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $124 | Reiterates | May 11, 2023 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $124 | Reiterates | May 9, 2023 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $124 | Reiterates | Mar 6, 2023 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $124 | Reiterates | Jan 24, 2023 |
| Mayank Mamtani B. Riley Securities | Buy | $44 | Maintains | Aug 11, 2022 |
| Mayank Mamtani B. Riley Securities | Buy | $72 | Maintains | Jan 24, 2022 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $124 | Maintains | Jul 20, 2021 |
| Mayank Mamtani B. Riley Securities | Buy | $111 | Maintains | Jun 23, 2021 |
B. Riley Securities | Buy | Initiates | Apr 27, 2021 | |
B. Riley FBR | Buy | Initiates | Apr 27, 2021 | |
JonesTrading | Buy | Initiates | Mar 17, 2021 |
When did it IPO
N/A
Staff Count
29
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Remi Barbier
Market Cap
$1.38B
In 2023, SAVA generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that SAVA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 03 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cassava Sciences, Inc. (Nasdaq: SAVA) will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York, highlighting its focus on Alzheimer's disease.
Why It Matters - Cassava Sciences' presentation at a major investment conference could boost visibility and investor interest, potentially impacting stock performance and future funding opportunities.
Sat, 10 Aug 2024
Sentiment - NEUTRAL
Source - MarketBeat
Summary - Cassava Sciences (NASDAQ: SAVA) shares surged 133% in the past month, now over 190% above their 52-week low, attracting significant trader interest due to increased volatility and liquidity.
Why It Matters - Cassava Sciences' 133% surge and high volatility indicate strong market interest, creating potential trading opportunities and risks for investors looking to capitalize on price movements.
Tue, 06 Aug 2024
Sentiment - NEUTRAL
Source - InvestorPlace
Summary - Cassava Sciences (NASDAQ: SAVA) is trending among traders today, indicating heightened interest. Investors should monitor this stock closely for potential opportunities.
Why It Matters - Cassava Sciences trending stock can indicate increased trading volume and volatility, potentially leading to price fluctuations that traders might capitalize on for profit.
Thu, 08 Aug 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Cassava Sciences reported Q2 earnings and plans to release Phase 3 study data for Alzheimer's drug simufilam in 2024, amid an SEC investigation and recent executive resignations.
Why It Matters - Cassava's Q2 earnings and upcoming Phase 3 study data are crucial for assessing its Alzheimer's drug's potential. Leadership changes and an SEC investigation raise concerns about stability and transparency.
Tue, 06 Aug 2024
Sentiment - NEUTRAL
Source - Schaeffers Research
Summary - Biotech stocks are in focus after a historically strong month for the SPDR S&P Biotech ETF (XBI), indicating potential investment opportunities in the sector.
Why It Matters - A historically bullish month for the SPDR S&P Biotech ETF (XBI) suggests strong investor confidence in biotech, potentially driving stock prices and influencing investment strategies.
Mon, 05 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cassava Sciences, Inc. (Nasdaq: SAVA) announced the passing of long-time board member Sanford Robertson on August 5, 2024.
Why It Matters - The passing of a long-time board member may signal potential changes in leadership or strategy at Cassava Sciences, impacting investor confidence and future company direction.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
